In vitro antifungal activity of epigallocatechin 3-O-gallate against clinical isolates of dermatophytes

Bong Joo Park, Hideaki Taguchi, Katsuhiko Kamei, Tetsuhiro Matsuzawa, Suong Hyu Hyon, Jong Chul Park

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Previously, we reported that epigallocatechin 3-O-gallate (EGCg) has growth-inhibitory effect on clinical isolates of Candida species. In this study, we investigated the antifungal activity of EGCg and antifungal agents against thirty-five of dermatophytes clinically isolated by the international guidelines (M38-A2). All isolates exhibited good susceptibility to EGCg (MIC50, 2-4 μg/mL, MIC90, 4-8 μg/mL, and geometric mean (GM) MICs, 3.36-4 μg/mL) than those of fluconazole (MIC50, 2-16 μg/mL, MIC90, 4-32 μg/mL, and GM MICs, 3.45-25.8 μg/mL) and flucytosin (MIC50, MIC90, and GM MICs, >64 μg/mL), although they were less susceptible to other antifungal agents, such as amphotericin B, itraconazole, and miconazole. These activities of EGCg were approximately 4-fold higher than those of fluconazole, and were 4 to 16-fold higher than flucytosin. This result indicates that EGCg can inhibit pathogenic dermatophyte species. Therefore, we suggest that EGCg may be effectively used solely as a possible agent or combined with other antifungal agents for antifungal therapy in dermatophytosis.

Original languageEnglish
Pages (from-to)535-538
Number of pages4
JournalYonsei medical journal
Volume52
Issue number3
DOIs
Publication statusPublished - 2011 May 1

Fingerprint

Arthrodermataceae
Antifungal Agents
Fluconazole
Miconazole
Tinea
Itraconazole
Amphotericin B
Candida
varespladib methyl
epigallocatechin gallate
In Vitro Techniques
Guidelines
Growth

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Park, Bong Joo ; Taguchi, Hideaki ; Kamei, Katsuhiko ; Matsuzawa, Tetsuhiro ; Hyon, Suong Hyu ; Park, Jong Chul. / In vitro antifungal activity of epigallocatechin 3-O-gallate against clinical isolates of dermatophytes. In: Yonsei medical journal. 2011 ; Vol. 52, No. 3. pp. 535-538.
@article{4dd30f795df048928143084ea24eefa0,
title = "In vitro antifungal activity of epigallocatechin 3-O-gallate against clinical isolates of dermatophytes",
abstract = "Previously, we reported that epigallocatechin 3-O-gallate (EGCg) has growth-inhibitory effect on clinical isolates of Candida species. In this study, we investigated the antifungal activity of EGCg and antifungal agents against thirty-five of dermatophytes clinically isolated by the international guidelines (M38-A2). All isolates exhibited good susceptibility to EGCg (MIC50, 2-4 μg/mL, MIC90, 4-8 μg/mL, and geometric mean (GM) MICs, 3.36-4 μg/mL) than those of fluconazole (MIC50, 2-16 μg/mL, MIC90, 4-32 μg/mL, and GM MICs, 3.45-25.8 μg/mL) and flucytosin (MIC50, MIC90, and GM MICs, >64 μg/mL), although they were less susceptible to other antifungal agents, such as amphotericin B, itraconazole, and miconazole. These activities of EGCg were approximately 4-fold higher than those of fluconazole, and were 4 to 16-fold higher than flucytosin. This result indicates that EGCg can inhibit pathogenic dermatophyte species. Therefore, we suggest that EGCg may be effectively used solely as a possible agent or combined with other antifungal agents for antifungal therapy in dermatophytosis.",
author = "Park, {Bong Joo} and Hideaki Taguchi and Katsuhiko Kamei and Tetsuhiro Matsuzawa and Hyon, {Suong Hyu} and Park, {Jong Chul}",
year = "2011",
month = "5",
day = "1",
doi = "10.3349/ymj.2011.52.3.535",
language = "English",
volume = "52",
pages = "535--538",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "3",

}

In vitro antifungal activity of epigallocatechin 3-O-gallate against clinical isolates of dermatophytes. / Park, Bong Joo; Taguchi, Hideaki; Kamei, Katsuhiko; Matsuzawa, Tetsuhiro; Hyon, Suong Hyu; Park, Jong Chul.

In: Yonsei medical journal, Vol. 52, No. 3, 01.05.2011, p. 535-538.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro antifungal activity of epigallocatechin 3-O-gallate against clinical isolates of dermatophytes

AU - Park, Bong Joo

AU - Taguchi, Hideaki

AU - Kamei, Katsuhiko

AU - Matsuzawa, Tetsuhiro

AU - Hyon, Suong Hyu

AU - Park, Jong Chul

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Previously, we reported that epigallocatechin 3-O-gallate (EGCg) has growth-inhibitory effect on clinical isolates of Candida species. In this study, we investigated the antifungal activity of EGCg and antifungal agents against thirty-five of dermatophytes clinically isolated by the international guidelines (M38-A2). All isolates exhibited good susceptibility to EGCg (MIC50, 2-4 μg/mL, MIC90, 4-8 μg/mL, and geometric mean (GM) MICs, 3.36-4 μg/mL) than those of fluconazole (MIC50, 2-16 μg/mL, MIC90, 4-32 μg/mL, and GM MICs, 3.45-25.8 μg/mL) and flucytosin (MIC50, MIC90, and GM MICs, >64 μg/mL), although they were less susceptible to other antifungal agents, such as amphotericin B, itraconazole, and miconazole. These activities of EGCg were approximately 4-fold higher than those of fluconazole, and were 4 to 16-fold higher than flucytosin. This result indicates that EGCg can inhibit pathogenic dermatophyte species. Therefore, we suggest that EGCg may be effectively used solely as a possible agent or combined with other antifungal agents for antifungal therapy in dermatophytosis.

AB - Previously, we reported that epigallocatechin 3-O-gallate (EGCg) has growth-inhibitory effect on clinical isolates of Candida species. In this study, we investigated the antifungal activity of EGCg and antifungal agents against thirty-five of dermatophytes clinically isolated by the international guidelines (M38-A2). All isolates exhibited good susceptibility to EGCg (MIC50, 2-4 μg/mL, MIC90, 4-8 μg/mL, and geometric mean (GM) MICs, 3.36-4 μg/mL) than those of fluconazole (MIC50, 2-16 μg/mL, MIC90, 4-32 μg/mL, and GM MICs, 3.45-25.8 μg/mL) and flucytosin (MIC50, MIC90, and GM MICs, >64 μg/mL), although they were less susceptible to other antifungal agents, such as amphotericin B, itraconazole, and miconazole. These activities of EGCg were approximately 4-fold higher than those of fluconazole, and were 4 to 16-fold higher than flucytosin. This result indicates that EGCg can inhibit pathogenic dermatophyte species. Therefore, we suggest that EGCg may be effectively used solely as a possible agent or combined with other antifungal agents for antifungal therapy in dermatophytosis.

UR - http://www.scopus.com/inward/record.url?scp=79955667472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955667472&partnerID=8YFLogxK

U2 - 10.3349/ymj.2011.52.3.535

DO - 10.3349/ymj.2011.52.3.535

M3 - Article

C2 - 21488200

AN - SCOPUS:79955667472

VL - 52

SP - 535

EP - 538

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 3

ER -